MedTrace Logo

Genecept Assay and Adverse Effects of Antidepressants

NCT02883660 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 74

Last updated 2018-03-16

No results posted yet for this study

Summary

The purpose of this study is to determine whether patients who have been prescribed antidepressant medications and have experienced significant adverse effects are more likely to be poor metabolizers on the CYP450 (CYP2B6, CYP2D6, CYP2C19, CYP3A4/5+) drug metabolizing enzymes and/or homozygous for the short allele of the serotonin transporter (SLC6A4) compared to patients who took an antidepressant medication and did not experience significant adverse effects but also had minimal or no response to the medication. The target medications being studied include escitalopram, citalopram, paroxetine, fluvoxamine, venlafaxine, duloxetine, bupropion, vortioxetine, vilazodone, and levomilnacipran only.

Conditions

Interventions

GENETIC

Genocept Assay

battery of pharmacogenetic tests relevant to psychiatry

Sponsors & Collaborators

  • Thomas Jefferson University

    lead OTHER

Principal Investigators

  • William Jangro, MD · Thomas Jefferson University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2017-07-01
Completion
2018-02-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02883660 on ClinicalTrials.gov